Something’s happening up in Boulder, and it’s not another craft beer startup; it’s VitriVax turning vaccine science into something out of a sci-fi novel. This isn’t your standard biotech story; it’s what happens when a virologist and an engineer decide cold storage is a problem worth eliminating and build an entire platform around it. Co-founders Robert Garcea and Theodore (Ted) Randolph took the kind of academic collaboration most people write papers about and turned it into a company that’s now redefining how vaccines survive the real world.
VitriVax just locked in $17.25M in Series B funding, co-led by Adjuvant Capital and RA Capital Management. Add that to a $9.9M Gates Foundation grant earlier this month, $5M from CEPI for rabies work, $3.6M from Gates for polio, and a $29M DoD contract, and you start to see the pattern. When every heavyweight in global health and defense lines up behind your tech, you’re not pitching potential; you’re proving it.
CEO Romulo Colindres isn’t new to this arena. Fifteen years in vaccines, former VP of Global Medical Affairs for GSK’s zoster vaccine, MD/MPH/MBA credentials that read like a clinical manual for execution. Add VP of Operations Kim Erickson, Ph.D., leading the $28M DTRA contract, and you’ve got a leadership core that blends scientific depth with operational precision. They’ve grown from 19 employees to more than 50 in just 3 years, proof that momentum follows substance.
The science? The ALTA® platform, Atomic Layering Thermostable Antigen and Adjuvant, isn’t just a cool acronym; it’s the kind of tech that laughs in the face of 70°C heat. Imagine a single shot that carries its own booster, stable for months without a cold chain, designed for places where refrigeration means a cooler under a tree. Spray-dried antigens sealed in sugar glass, nanometer coatings controlling release timing like a metronome. It’s elegant chemistry meeting real-world logistics.
This $17.25M round fuels ALTA’s march toward human clinical trials, scaling GMP manufacturing and regulatory readiness. VitriVax’s HQ at 5500 Central Ave, Boulder, is becoming the launchpad for a new era where vaccines travel better than tourists. Partnerships with the Serum Institute of India, University of Nevada Reno, and Latham BioPharm Group back that mission with serious muscle.
VitriVax is solving a logistics problem that’s haunted global health for decades. The world doesn’t need more vaccines; it needs vaccines that can survive the trip. That’s the quiet revolution happening in Boulder, funded by believers and built by people who refuse to let refrigeration decide who gets protection.
